[Update Treatment HPV-16-positive Oropharyngeal Carcinoma]

Laryngorhinootologie. 2021 Oct;100(10):832-844. doi: 10.1055/a-1523-9045. Epub 2021 Oct 6.
[Article in German]

Abstract

Background: Oropharynx carcinoma (OPSCC) is a genetically heterogeneous tumor group with high prognostic diversity due to its worldwide increase in incidence and the association with the human papillomavirus HPV 16, but also chronic tobacco/alcohol consumption.

Objective: The review attempts to present the current view on therapy and prevention of OPSCC with respect to association with HPV 16.

Material & methods: The overview is based on the current relevant literature as well as current studies.

Results & discussion: The OPSCC presents itself as a very complex, genetically heterogeneous group of head and neck tumors, which should therefore be considered in detail. The currently contradictory trial situation of retrospective studies versus prospective trials, the current TNM classification (8th edition) and the scarce prospective data arguing for non-inferiority of therapy de-intensification attempts currently admonish to encourage a more conservative treatment.

Publication types

  • Review

MeSH terms

  • Carcinoma*
  • Human papillomavirus 16 / genetics
  • Humans
  • Oropharyngeal Neoplasms* / therapy
  • Papillomavirus Infections* / therapy
  • Prognosis
  • Prospective Studies
  • Retrospective Studies